plinabulin plinabulin plinabulin (provisional name bpi-2358, formerly npi-2358) is a small molecule under development by beyondspring pharmaceuticals, and is in a world-wide phase 3 clinical trial for non-small cell lung cancer. plinabulin is being investigated for the reduction of chemotherapy-induced neutropenia and for anti-cancer effects in combination with immune checkpoint inhibitors and in kras mutated tumors. plinabulin names iupac name (3z,6z)-3-benzylidene-6--2,5-piperazinedione identifiers cas number 714272-27-2 y 3d model (jsmol) interactive image chebi chebi:177413 chemspider 8125252 kegg d09655 pubchem cid 9949641 unii 986fy7f8xr y inchi inchi=1s/c19h20n4o2/c1-19(2,3)16-13(20-11-21-16)10-15-18(25)22-14(17(24)23-15)9-12-7-5-4-6-8-12/h4-11h,1-3h3,(h,20,21)(h,22,25)(h,23,24)/b14-9-,15-10-key: unrcmcrrfyfgfx-typnbtcfsa-ninchi=1/c19h20n4o2/c1-19(2,3)16-13(20-11-21-16)10-15-18(25)22-14(17(24)23-15)9-12-7-5-4-6-8-12/h4-11h,1-3h3,(h,20,21)(h,22,25)(h,23,24)/b14-9-,15-10-key: unrcmcrrfyfgfx-typnbtcfbu smiles o=c3/c(=c/c1ncc1c(c)(c)c)nc(=o)c(=c\c2ccccc2)\n3 properties chemical formula c19h20n4o2 molar mass 336.395 g·mol−1 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). infobox references plinabulin blocks the polymerization of tubulin in a unique manner, resulting in multi-factorial effects including an enhanced immune-oncology response, activation of the jnk pathway and disruption of the tumor blood supply.